Related Experiment Video
Updated: Feb 10, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis
Ioannis Andreou1, Alexandros Briasoulis2, Christos Pappas1
12nd Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Rimini 1, Chaidari, 124 62, Athens, Greece.
Insights
Ticagrelor increases bleeding risk compared to clopidogrel in patients needing antiplatelet therapy and oral anticoagulation. Ticagrelor may also raise adverse cardiovascular events in triple therapy patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Clopidogrel is the standard P2Y12 receptor inhibitor for patients requiring both antiplatelet therapy and oral anticoagulation (OAC).
- Investigating ticagrelor as an alternative to clopidogrel in this patient population is crucial for optimizing treatment strategies.
Purpose of the Study:
- To evaluate the safety and efficacy of ticagrelor compared to clopidogrel in patients on oral anticoagulation (OAC).
Main Methods:
- A systematic literature search was conducted across MEDLINE, EMBASE, and the Cochrane Library.
- Randomized controlled trials comparing clopidogrel and ticagrelor in patients on antiplatelet agents plus OAC were included.
Main Results:
- Three trials involving 5659 patients were analyzed.
- Ticagrelor significantly increased the risk of clinically significant bleeding in both dual and triple antithrombotic therapy groups compared to clopidogrel.
- In triple therapy, ticagrelor was associated with a higher risk of major adverse cardiovascular events (MACE), while dual therapy showed similar MACE and stroke risks.
Conclusions:
- Ticagrelor use in dual or triple antithrombotic therapy is linked to increased bleeding complications versus clopidogrel.
- Ticagrelor may elevate the risk of thromboembolic and ischemic cardiac events in patients on triple therapy.
Purpose:
Clopidogrel is the standard P2Y12 receptor inhibitor used in patients requiring both antiplatelet therapy and oral anticoagulation (OAC). We investigated the safety and efficacy of ticagrelor as an alternative to clopidogrel in patients on OAC.
Methods:
A systematic electronic literature search was performed in MEDLINE, EMBASE, and the Cochrane Library for randomised controlled studies that examined the relative safety and efficacy of clopidogrel versus ticagrelor among patients requiring therapy with antiplatelet agents plus OAC.
Results:
Three randomised controlled trials were identified with a total of 5659 patients. The risk of clinically significant bleeding was significantly increased among patients on dual or triple antithrombotic therapy who received ticagrelor compared with patients on clopidogrel (OR 1.52, 95% CI 1.12 to 2.06, and OR 1.7, 95% CI 1.24 to 2.33, respectively). Among those on triple therapy, ticagrelor was associated with a significantly higher risk of major adverse cardiovascular events (MACE) compared to clopidogrel (OR 1.88, 95% CI 1.26 to 2.80). Patients who received dual therapy exhibited similar risk of MACE and stroke with ticagrelor versus clopidogrel (OR 1.14, 95% CI 0.83 to 1.56, and OR 0.42, 95% CI 0.10 to 1.74, respectively).
Conclusion:
The use of ticagrelor as part of dual or triple antithrombotic therapy is associated with significantly higher rates of clinically relevant haemorrhagic complications compared with clopidogrel. Among triple therapy-treated patients, the use of ticagrelor might increase thromboembolic and ischaemic cardiac events.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups
Systematic Sampling Method
Systematic sampling is one of the simplest methods...
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
